鶹ýӰ

LVAD Monitoring App Recall; ADHD Drug & CVD Risk; Value of ATTR Treatments?

— Recent developments of interest in cardiovascular medicine

MedpageToday
Cardio Break over a computer rendering of a heart.

The FDA announced the class I recall of an using the HeartMate 3 Left Ventricular Assist Device (LVAD), as well as updated guidance related to the troublesome "Stop Pump" command; the recall is a correction rather than a product removal.

Patients prescribed for attention deficit-hyperactivity disorder (ADHD) had a small signal for short-term increased cardiovascular risk. (JAMA Network Open)

Breaking from a highly sedentary lifestyle to take was associated with cardiovascular benefit. (British Journal of Sports Medicine)

The Institute for Clinical and Economic Review said it will review : acoramidis, tafamidis (Vyndamax), and vutrisiran (Amvuttra).

In evaluating transthyretin amyloidosis, a worse amyloid burden went hand in hand with , a cohort study found. (JAMA Cardiology)

A CDC study showed that from 2017 to 2021, the overall prevalence of adult hypertension was unchanged but from 60% to 63%. (Morbidity and Mortality Weekly Report)

Black people did not show as strong a link between in a population-based cohort study. (Neurology)

In a 5-year follow-up of the EXCEL trial, hospital readmission rates gave surgery the upper hand over angioplasty for . (Journal of the American College of Cardiology)

A pooled analysis of four trials showed the clinical tradeoffs of treating with percutaneous coronary intervention (PCI) or coronary artery bypass grafting. (Circulation)

predicted mortality in people with ST-segment elevation myocardial infarction undergoing PCI. (European Journal of Preventive Cardiology)

The PCSK9 inhibitor was FDA approved for LDL cholesterol reduction in children ages 8 years and older with heterozygous familial hypercholesterolemia, Regeneron announced.

Over half of Native American teens and young adults in a prospective cohort study. (Journal of the American Heart Association)

Bodyport said that with its for remote heart failure monitoring, more heart failure events could be detected as compared with standard of care.

Certain markers may identify people with heart failure more likely to benefit from , based on the IRONMAN trial. (European Heart Journal)

WhiteSwell announced that its , in conjunction with loop diuretics, was associated with reduced tissue congestion in people with acute decompensated heart failure in the DELTA-HF study.

Using a led to faster procedures with less radiation exposure and similar success rates. (Clinical Cardiology)

  • author['full_name']

    Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine.